Urinary NGAL Acute Kidney Injury After Stored Red Blood Cells Transfusion in Critically Ill Patients.
June 15, 2018 updated by: Tarek Samy Abdelziz, Kasr El Aini Hospital
The Association of NGAL With the Development of Acute Kidney Injury After Stored Red Blood Cells Transfusion in Critically Ill Patients.
The study aims to explore the association of the novel urinary bio marker NGAL with the age of PRBCs(packed red blood cells) transfusion in critically ill patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators will measure the urinary NGAL in all patients who received blood transfusion in the intensive care unit during the study period.
The age of PRBCs transfusion will be correlated with the incidence of AKI.
The rise of NGAL and serum creatinine will be used to diagnose AKI (Acute Kidney Injury).
Study Type
Observational
Enrollment (Actual)
147
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- Cairo university hospitals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult patients admitted to ICU of any age and sex
Description
Inclusion Criteria:
- Any patients admitted to the intensive care unit.
Exclusion Criteria:
- patients who have established AKI at the time of recruitment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Stored blood transfusion
measurement of urinary NGAL
|
measurement urinary NGAL using the ARCHITECT technique
|
|
Fresh blood transfusion
measurement of urinary NGAL
|
measurement urinary NGAL using the ARCHITECT technique
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of AKI
Time Frame: within 30 days
|
Diagnosis of AKI by rise of serum creatinine
|
within 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Tarek Abdelaziz, faculty of medicine-Cairo University Hospitals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 2, 2017
Primary Completion (Actual)
December 5, 2017
Study Completion (Actual)
December 5, 2017
Study Registration Dates
First Submitted
June 5, 2018
First Submitted That Met QC Criteria
June 15, 2018
First Posted (Actual)
June 18, 2018
Study Record Updates
Last Update Posted (Actual)
June 18, 2018
Last Update Submitted That Met QC Criteria
June 15, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KA-13115
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.